source
- Experts discuss emerging MET-driven resistance data shaping second-line therapy for EGFR-mutated lung cancerIn a recent video segment, Dr. Jacob Sands sits down with Dr. Heather Wakelee to talk about the impact of new findings on MET-driven resistance in EGFR‑mutated non‑small cell lung cancer. The conv…
- Sequencing antibody-drug conjugates adds complexity to recurrent endometrial cancer treatmentTherapy sequencing for recurrent endometrial cancer is becoming increasingly complex as immunotherapy moves earlier in the treatment pathway and antibody-drug conjugates (ADCs) gain traction. Expe…